Results 71 to 80 of about 41,420 (299)

Macrophage Extracellular Traps in Immunity and Cancer

open access: yesAdvanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li   +5 more
wiley   +1 more source

Challenges and perspectives in using unspecific peroxygenases for organic synthesis

open access: yesFrontiers in Catalysis
In the past 20 years, unspecific peroxygenases (UPOs) have emerged as promising biocatalysts for various organic transformations. Particularly, we have witnessed great attention being paid to the screening of new enzymes and expansion of the substrates ...
Yawen Huang   +7 more
doaj   +1 more source

Succinate : quinone oxidoreductases from epsilon-proteobacteria [Review]

open access: yes, 2002
The epsilon-proteobacteria form a subdivision of the Proteobacteria including the genera Wolinella, Campylobacter, Helicobacter, Sulfurospirillum, Arcobacter and Dehalospirillum.
Lancaster, C. R. D.   +6 more
core   +1 more source

Disruption of Treg Homeostasis in Rheumatoid Arthritis via Ferroptosis‐Mediated ETC Collapse and TXK‐STAT3/PLCγ1 Activation

open access: yesAdvanced Science, EarlyView.
In rheumatoid arthritis, synovial Tregs accumulate but are functionally impaired due to iron overload‐induced ferroptosis. This triggers mitochondrial dysfunction and TXK tyrosine kinase‐mediated signaling, leading to Treg destabilization and inflammation.
Jingrong Chen   +19 more
wiley   +1 more source

Cofactor regeneration by a soluble pyridine nucleotide transhydrogenase for biological production of hydromorphone [PDF]

open access: yes, 2000
We have applied the soluble pyridine nucleotide transhydrogenase of Pseudomonas fluorescens to a cell-free system for the regeneration of the nicotinamide cofactors NAD and NADP in the biological production of the important semisynthetic opiate drug ...
French, C E   +4 more
core   +1 more source

oxidoreductases

open access: yes, 2014
Citation: 'oxidoreductases' in the IUPAC Compendium of Chemical Terminology, 3rd ed.; International Union of Pure and Applied Chemistry; 2006. Online version 3.0.1, 2019. 10.1351/goldbook.O04370 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Tailored Porous Bimetallic Nanozyme Platform for Full‐Cycle Therapeutics of Intestinal Ischemia/Reperfusion

open access: yesAdvanced Science, EarlyView.
ABSTRACT Intestinal ischemia/reperfusion (I/R) injury presents a biphasic pathology: an acute oxidative‐inflammatory phase leading to organ failure, and a recovery phase marked by mucosal dysfunction and bacterial translocation. The developed MPB@TA‐Cu‐Ma nanocomposite functions as a dual‐phase therapeutic platform with significant efficacy. It rapidly
Chenghao Qiu   +15 more
wiley   +1 more source

Serological Diagnosis of Liver Metastasis in Patients with Breast Cancer

open access: yesCancer Biology & Medicine, 2012
Objective To diagnose and explore the serological diagnostic factors for liver metastasis in patients with breast cancer before symptoms occur.Methods A total of 430 female in-patients with breast cancer of stages 0 to IIIC who came to Tianjin Medical ...
Rui Cao, Li-ping Wang
doaj   +3 more sources

GHRHR Deficiency Enhances Retinal Ganglion Cell Survival and Visual Functions in Experimental Glaucoma by Inhibiting Ferroptosis

open access: yesAdvanced Science, EarlyView.
Glaucoma, a major cause of blindness, involves retinal ganglion cell (RGC) degeneration. This study shows growth hormone‐releasing hormone receptor (GHRHR) deficiency preserves RGC survival and restores vision, unlike activation which only aids survival.
Yan Tong   +24 more
wiley   +1 more source

Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.

open access: yes, 2012
The clinical agent PR-104 is converted systemically to PR-104A, a nitrogen mustard prodrug designed to target tumor hypoxia. Reductive activation of PR-104A is initiated by one-electron oxidoreductases in a process reversed by oxygen.
Nair, Smitha   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy